|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.34/-0.30
|
企业价值
539.05M
|
资产负债 |
每股账面净值
2.02
|
现金流量 |
现金流量率
--
|
损益表 |
收益
41.29M
|
每股收益
0.39
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/21 08:56 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies. |